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Abstract
Objectives: To investigate the prevalence of NAFLD as well as the determination of associated 
metabolic abnormalities in Iranian blood donors. The aim of this study was to review cases of non-
alcoholic fatty liver disease and to determine the prevalence of non-alcoholic fatty liver disease as a 
cause of elevated alanine aminotransferase in healthy blood donors and also assess risk factors of 
NAFLD such as BMI and correlation with metabolic syndrome in these subjects.
Background: Non-alcoholic fatty liver disease has been increasingly recognized as the most 
common pathological conditions affecting the liver. Non-alcoholic fatty liver disease is now recognized 
as the hepatic component of the metabolic syndrome, which includes hyperlipidemia, glucose 
intolerance, obesity, and systemic hypertension.
Methods: This cross-sectional study was conducted among a sample of 479 blood donor aged 
between 17-66 years in Hamedan, Iran. The donor answered a questionnaire that included age, gender, 
and medical history, and were submitted to a complete physical exam and abdominal ultrasound. 
Biochemical exams included: ALT, AST, ALP, fasting glucose, cholesterol and triglycerides. Criteria for 
NAFLD included: the presence of steatosis in ultrasound and/or elevated ALT/AST with negative intake of 
alcohol, negative use of drug, negative investigation for hepatitis A, B, C, auto-immune hepatitis, Wilson 
disease and hemochromatosis.
Results: From August, 2012 to January, 2013, the study included 479 subjects between 17 and 66 
years of age and a mean age of 33.3 ± 10.5 years. The prevalence of NAFLD was 35.7% (mild 21.3%, 
moderate 13.4%, sever 1%). From lower to higher BMI category; alanine aminotransferase (ALT), total 
cholesterol, LDL cholesterol and triglycerides statistically increased significantly. In all BMI categories, 
ALT increased significantly by increasing the number of the components of the metabolic syndrome. 
Odds ratio for elevated liver enzymes and sonographic fatty liver increased significantly with higher BMI 
categories before and after adjustment for age.
Conclusion: There was a strong relationship between NAFLD and the abnormal metabolic 
variables in blood donors. It would be very useful if people are exposed to some determination such as 
waist circumference, blood pressure, FBS and serum lipid profile in order to screen those susceptible 
to NAFLD.
Materials and Methods
Population selection
In a cross-sectional study during six-month period from August, 
2012 to January, 2013, we collected data from in the Blood Donation 
Center of Hamedan, 479 healthy blood donors (age between 17-
66 years), were recruited in this study with no history of alcohol 
consumption and also any kind of liver diseases such as hepatitis and 
liver metabolic disease. According to the regulations of the Blood 
Transfusion Organization of Iran, the following individuals are not 
allowed to donate blood: those who have had major chronic disease, 
those with any mild to severe acute disease and intravenous drug 
users.
Exclusion criteria: Previous historic or serologic markers for 
liver diseases (hepatitis A, B, C), auto-immune disease, metabolic 
diseases such as Wilsons Disease and hemochromatosis and intake of 
alcohol above 140 g/wk. 
Introduction
Nonalcoholic fatty liver disease (NAFLD) is a clinico-
pathological condition of wide spectrum, which includes steatosis 
and steatohepatitis that has a potential to advance to cirrhosis and 
hepatocellular carcinoma [1]. NAFLD is probably the most common 
underlying cause of cryptogenic cirrhosis [2,3]. NAFLD is the most 
common liver disorder in the world, affecting 2.8% to 24% of the 
general population [4] and is the most common cause of persistently 
elevated serum ALT in the asymptomatic Iranian blood donors in 
Tehran [5]. In adults visceral obesity has been considered the main 
risk factor for the development of NAFLD [6,7]. Different studies 
have shown that NAFLD is associated with older age, diabetes 
mellitus, obesity and dyslipidemia (especially increased triglyceride) 
[8,9]. In most instances, an incidental finding of abnormal serum 
aminotransferase leads to the diagnosis of fatty liver or NAFLD in 
adults [10]. This study determined the prevalence of NAFLD as a 
cause of elevated alaninaminotransferase in healthy blood donors in 
hamedan and also risk factors of NAFLD, such as raised BMI and the 
metabolic syndrome in these subjects.
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Clinical evaluation
Demographic information, as well as baseline characteristics like 
age, drug and disease history was collected for each individual by 
trained interviewers.
Anthropometric measures: waist circumference (WC) was 
measured at the end of normal expiration in the middle portion 
between the last rib and the iliac ridge whereas hip circumference 
was similarly obtained at the widest point between the hip and the 
buttock. Participants were weighed while not wearing coats or shoes 
or carrying any objects. A Filizola balance was used, with a scale 
resolution of 0.1 kg. Height was measured by a stadiometer with no 
shoes and hair accessories; the resolution was 0.5 cm. BMI (Body 
Mass Index) was calculated by dividing weight by height squared 
and categorized according to the classification of National Heart, 
Lung and Blood Institute of the USA as follows: normal weight (18.5 
24.9kg/m2), overweight (25-29.9 kg/m2) and obese (30-34.9 kg/M2) 
[11].
All patients underwent superior abdomen ultrasound scan (AUS). 
The AUS was performed by only one medical doctor. The scanner 
used was an Aloka, model DynaView II, with colored Doppler and a 
3.5 MHz drill. The discrepancy of echogenicity between the liver and 
kidney was considered as a criterion. Hepatic steatosis was graded as 
mild, moderate or severe, according to the Saverumuttu et al. [12], 
classification. 
Serological assays
Blood samples were collected during the same session by the 
technical staff after a 12 h fasting. The samples were analyzed in a 
referential laboratory for Alanine aminotransferase(ALT) and 
aspartate aminotransferase (AST), Alkaline phosphatase(ALP), 
fasting blood sugar (FBS), total cholesterol, triglycerides (Tg), low-
density cholesterol (LDL-C), high-density cholesterol (HDL-C), and 
anti-HCV antibody (anti-HCV) with the use of a third generation 
ELISA test (Ortho HCV 3.0 Enhanced SAVe ELISA, Ortho-Clinical 
Diagnostics, Amer sham, UK and Hepanostika HCV Ultrakit, Beijing 
United Biomedical Co., Beijing, China),and HBsAg were also 
evaluated by an Enzygnost HBsAg 5.0 kit (Dade Behring, Germany). 
Normal upper limit for ALT was considered 40 units per liter (U/L).
Anthropometric measurements 
Anthropometric measurements of individuals wearing light 
clothing and without shoes were conducted by well-trained examiners.
Height was measured to the nearest 0.1 cm with a portable 
stadiometer.
Weight was measured in an upright position to the nearest 0.1 kg 
with a calibrated scale.
Body mass index was calculated by dividing weight (kg) by height 
squared (m²).
Waist circumference measurements were taken at the end 
of normal expiration to the nearest 0.1 cm, measuring from the 
narrowest point between the lower borders of the rib cage and the 
iliac crest , whereas hip circumferences was similarly obtained at the 
widest point between hip and buttock. 
Blood pressure measurements and biochemical 
analysis
A mercury sphygmomanometer (Baumanometer; WA Baum 
CO, Inc, Tokyo, Japan) was used to measure the blood pressure of 
each subject while in a sitting position after a 5-min rest period.
During the 30 minute preceding the measurement, the subjects 
were required to refrain from smoking or consuming caffeine.
The appearance of the first sound (phase 1 Korotkoff sound) 
was used to define systolic blood pressure, and the disappearance of 
sound (phase 5 Korotkoff sound) was used to define diastolic blood 
pressure.
Blood samples were collected from the antecubital vein in the 
morning where they had been fasted for 9-12 hours. The samples 
were subsequently analyzed at a central, certified laboratory. Plasma 
concentrations of glucose, total cholesterol, triglyceride, HDL 
cholesterol, and AST, ALT were measured with an auto analyzer.
Statistical analyses 
The data were analyzed using Statistical Package for Social 
Science (SPSS) 17.0. Mistake type was estimated to be 5%. Spearman 
was used for the correlation between variables. The data are expressed 
as percentage, medium and standard deviation. Weighted logistic 
regression analyses were used to calculate the odds ratio (OR) and 
95% confidence interval (95% CI) for each risk factor. A final logistic 
regression analysis was performed by a back ward model selection for 
age, sex, BMI, Multivariate logistic regression analysis was used to 
identify independent risk factors for NAFLD. All analyses were two-
tailed and P<0.05 was considered to be statistically significant. 
Results
The study included 479 subjects between 17 and 66 years of 
age and a mean age of 33.3 ± 10.5 years, 442(92.3%) were male and 
37(7.7%) female. There was no significant difference between sex 
(P>0.3).
BMI (Body Mass Index) in these 479 subjects ranged from 19.1 
to 38.2 and mean of BMI in all subjects was 28±4.3 .Overweight 
was observed in 201(42%) and obese 148(30.9%) of studied with 
central obesity. There was a positive correlation between BMI and 
WC values and the mean value of BMI was significantly higher in 
abnormal LFT than in normal LFT. The prevalence of elevated ALT 
as another diagnostic indicator was 25.3%. WC had a statistically 
significant correlation with ALT (P < 0.05). Fatty liver was diagnosed 
by ultrasound in 171(35.7%), divided between mild (21.3%), 
moderate (13.4%) and severe (1%). Non-alcoholic fatty liver disease 
was significantly more common in the hypertriglyceridemia and 
hypercholesterolemia (P<0.0001).The prevalence of NAFLD in obese, 
overweight and normal weight patients was 30.3%, 5.4% and 0.0% 
respectively (P<0.000) (Table 1). 
Discussion
Obesity is the most common entity associated with NAFLD and 
a significant risk factor for the development of fatty liver and is also 
predictive for the presence of fibrosis [13]. Many epidemiological 
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studies demonstrated a strong correlation between body mass index 
and the presence of fatty liver diagnosed by ultrasonography. 30 to 
100% of patients diagnosed with NAFLD are Obese [14], in obese 
persons 76% have NAFLD compare with 16% in normal weight 
persons [15]. BMI is an important predictor for hepatic steatosis. 
The risk of hepatic steatosis increase exponentially with the addition 
of each component of the metabolic syndrome. A study on 271 
nondiabetic subjects demonstrated that liver fat was 4-fold higher 
in subjects with than without the metabolic syndrome. Among the 
components of metabolic syndrome the best correlation of liver 
fat was with waist circumference both in women and in men [16]. 
Positive correlation between BMI and WC in patients, as observed in 
this study, is also a common finding related to cardiovascular disease 
in other studies [17,18]. The characteristics of disease appear to be 
similar to those in other studies. Gender has not been considered to 
be a risk factor for NAFLD [19].
The diagnosis of NAFLD is often established after the identification 
of abnormal serum aminotransferase. The gold standard for diagnosis 
is liver biopsy. Although the procedure is effective as a prognostic 
indicator, liver biopsy is invasive and costly. Sonography has been 
used in assessing NAFLD but is lacking in the ability to assess fibrosis 
[20]. The frequency of NAFLD measured by sonography, which is 
more compared with the ALT determination, is in agreement with 
that in the study of Franzese in Italy (reported as 53% in sonography 
vs 25% through ALT determination) on obese patients [21]. The 
prevalence of an isolated elevated ALT levels (cut-off value of 41/
UL for both men and women) after excluding individuals with viral 
hepatitis, alcohol and drug etiologies was 25.3% whereas 52(10.9%) of 
NAFLD had normal ALT. In the study which carried out on Tehran 
blood donation center prevalence elevated ALT reported 5.71% [22]. 
This prevalence in the Third National Health and Nutrition study 
of the population of the United States was 2.8% [23]. We found 
through sonography as a diagnostic method of NAFLD that elevated 
ALT and metabolic variables such as high total cholesterol, waist 
circumference, BMI and LDL were significantly associated with the 
disease. There are some reports from Korea and Mexico showing that 
the most important factors associated with NAFLD are high total 
cholesterol, LDL, triglyceride, ALT, insulin, obesity and low HDL 
[24,25], which confirms the results reported in our project. 
In conclusion, NAFLD in asymptomatic Iranian was most 
frequent among patients with central obesity. These patients came 
from an area in Iran where it is relevant to consider the proportion of 
Asian descendants, and the influence of ethnicity on the prevalence 
the NAFLD may be an important factor in this population. However, 
this hypothesis deserves future study.
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